Table 3.
Summary of Response in Phase 1 and Phase 2
| Response Type | HL/ALCL | HL | Total Population |
|---|---|---|---|
| Phase I (n=27/1) | Phase II (n=37) | Phase I/II (n=65) | |
| ORR | 17 (61%, 41–79) | 29 (78%, 62–91) | 46 (71%, 58–81) |
| CR | 5 (18%) | 16 (43%) | 21 (32%) |
| PR1 | 12 (43%) | 13 (35%) | 25 (38%) |
| SD | 4 (14%) | 5 (14%) | 9 (14%) |
| NE | 1 (4%) | 0 (0%) | 1 (2%) |
| POD | 6 (21%) | 3 (8%) | 9 (14%) |
Data provided are n (%, 95% CI) or n (%)
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; NE, not evaluable; POD, progression of disease
1
ALCL subject included in PR.